4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Recommendation of "Buy" by Brokerages

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have earned a consensus rating of “Buy” from the ten analysts that are covering the stock, MarketBeat reports. Ten research analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have issued ratings on the stock […]

Related Keywords

United States , Canada , Scott Bizily , Nasdaq , Healthcare Of Ontario Pension Plan Trust Fund , D Molecular Therapeutics Inc , Royal Bank , Goldman Sachs Group , Barclays , Goldman Sachs Group Inc , Redmile Group , Vanguard Group Inc , Molecular Therapeutics , Get Free Report , Sachs Group , Ontario Pension Plan Trust Fund , Vanguard Group , Molecular Therapeutics Price , Get Free , Molecular Therapeutics Daily ,